Laura Bukavina, Urologic Oncologist at Cleveland Clinic and Assistant Professor of Urologic Oncology at Case Western Reserve University, shared a post on X:
“Our uber talented research fellow Gabriela M. Díaz, presenting real world data of Adstiladrin at WSAUA25, showing durable response among 108 patients with 86.1% showing no further treatment required (limited follow up <12mo).”
You can also read: Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More
